ALFA Finder| Revenue growth | 15.2% Y-o-Y for FY26. |
|---|---|
| Margins | EBITDA margin 11.9% for FY26; impacted by raw material inflation. |
| Demand visibility | Healthy double-digit growth in HPPC, TSC, and AHN segments. |
| Management confidence | High, citing strong R&D and balanced end-market exposure. |
Growth
FY26 revenue grew 15.2% to ₹2,396.4 cr; PAT grew 9.4% to ₹149.2 cr. Q4 revenue surged 18.2% Y-o-Y.
Outlook
Unitop commissioned 15,000 MTPA ethoxylation capacity. FY27-28 focus on rephased capex, R&D at Koparkhairane, and international expansion.
Risks
Raw material price volatility and lag in passing on cost inflation impacted quarterly margins (11.3% vs 12.0% Y-o-Y).
Earnings Call filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹432.80
- Market cap
- ₹2,397 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 15.7×Sector 35.5×
- Promoter holding
- 68.14%+0.00% QoQ
- FII holding
- 1.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Earnings Call Transcript: Key Takeaways
Rossari Biotech achieved record quarterly revenue and EBITDA despite volatile raw material costs and logistical headwinds.
- Call
- Guides 15% growth
Rossari Biotech Results Update
Rossari Biotech reported Q2 FY27 revenue of Rs. 697.6 crore, up 19% YoY. The company also announced plans for a new manufacturing facility in Saudi Arabia.
Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech reported record quarterly revenue of Rs. 697.6 Cr (up 19% YoY) and EBITDA of Rs. 87 Cr (up 21% YoY). Performance driven by volume and product mix.
Rossari Biotech Q2 FY27 Results: Net Profit ₹38.9 Cr, Up 5.4% YoY
Rossari Biotech Ltd reported revenue from operations of ₹697.6 Cr (+19.0% YoY) and net profit of ₹38.9 Cr (+5.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹38.9 Cr · +5.4% YoY
Rossari Biotech Other Announcement
Rossari Biotech submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing includes minor reporting adjustments for two promoter group members.
Rossari Biotech Board Meeting Date
Rossari Biotech will hold a board meeting on October 17, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.